O&G · Neonatal care — metabolic and transitional care
Neonatal hypoglycaemia
Also known as Neonatal hypoglycemia · Low blood glucose in the newborn · Neonatal low glucose · Hypoglycaemia of the newborn · Operational threshold hypoglycaemia
Exam-exhaustive FRANZCOG fellowship reference on neonatal hypoglycaemia — the at-risk groups, the operational-threshold concept and the Queensland Clinical Guideline age-stratified blood glucose targets, buccal dextrose gel 200 mg/kg with the Sugar Babies and Cochrane evidence, intravenous and glucagon escalation, and the neurodevelopmental outcome evidence (CHYLD, HypoEXIT). ANZ-primary, globally tagged.
Checked against its sources on 13 Oct 2026
On this page
Study tools
Your progress
Saved on this device.
Target exams
Red flags
- Treating a number without asking why — a low glucose is an operational trigger, not a diagnosis; the baby who needs investigation is the one who is recurrent, prolonged or symptomatic
- Gel and hoping when the glucose is under 1.5 mmol/L — that is critical hypoglycaemia; establish intravenous access and escalate now
- A reagent-strip point-of-care device that is not validated at low concentrations — confirm before you act on a number that may be wrong
- Exceeding the gel dosing ceiling — 2 doses in 24 hours, 5 doses total, 2 consecutive — repeated buccal gel hides a baby who needs a line
- The infant of a diabetic mother who is jittery at 90 minutes — the commonest, the most predictable, and the one still missed when feeding is delayed
- A glucose that will not rise past 8 mg/kg/minute of glucose infusion rate in the first 24 hours — think hyperinsulinism and measure the insulin, cortisol and ketones
It is 90 minutes since a 36-week baby of a mother with diet-controlled gestational diabetes was born. He is on the postnatal ward, jittery, and the midwife has just rung: the blood glucose is 1.8 mmol/L. Most neonatal hypoglycaemia is asymptomatic, predictable and reversible — but it remains the commonest metabolic emergency of the newborn and the one obstetricians see first, because the risk starts on the antenatal sheet. This topic is the sequence from risk to resolution, written for the obstetrician at the bedside.[1]
Overview — the operational threshold
Two facts frame the whole topic and examiners test both. First, neonatal glucose is normally low: a healthy term baby's blood glucose falls to a nadir in the first one to two hours and only slowly climbs toward adult concentrations. Second, no single glucose concentration separates a brain at risk from a brain that is fine.[1]
The consequence is the operational threshold — a pragmatic glucose value at which you act, chosen because the evidence will not give you a single number. The American Academy of Pediatrics frames it as a practical guide to screening and management, and the Pediatric Endocrine Society extends it upward beyond 48 hours. Both rest on the same admission: current evidence does not support a specific concentration that discriminates normal from abnormal, or that reliably predicts irreversible neurological damage.[1][2]
References11ShowHide
- [1]Adamkin DH Postnatal glucose homeostasis in late-preterm and term infants Pediatrics, 2011.PMID 21357346
- [2]Thornton PS, Stanley CA, De Leon DD, et al. Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children J Pediatr, 2015.PMID 25957977
- [3]Harris DL, Weston PJ, Signal M, et al. Dextrose gel for neonatal hypoglycaemia (the Sugar Babies Study): a randomised, double-blind, placebo-controlled trial Lancet, 2013.PMID 24075361
- [4]Weston PJ, Harris DL, Battin M, et al. Oral dextrose gel for the treatment of hypoglycaemia in newborn infants Cochrane Database Syst Rev, 2016.PMID 27142842
- [5]Edwards T, Liu G, Battin M, et al. Oral dextrose gel for the treatment of hypoglycaemia in newborn infants Cochrane Database Syst Rev, 2022.PMID 35302645
- [6]Harding JE, Hegarty JE, Crowther CA, et al. Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): A multicenter, double-blind randomized controlled trial PLoS Med, 2021.PMID 33507929
- [7]Edwards T, Alsweiler JM, Crowther CA, et al. Prophylactic Oral Dextrose Gel and Neurosensory Impairment at 2-Year Follow-up of Participants in the hPOD Randomized Trial JAMA, 2022.PMID 35315885
- [8]McKinlay CJ, Alsweiler JM, Ansell JM, et al. Neonatal Glycemia and Neurodevelopmental Outcomes at 2 Years N Engl J Med, 2015.PMID 26465984
- [9]van Kempen AAMW, Eskes PF, Nuytemans DHGM, et al. Lower versus Traditional Treatment Threshold for Neonatal Hypoglycemia N Engl J Med, 2020.PMID 32023373
- [11]Queensland Clinical Guidelines Hypoglycaemia–newborn (MN23.8-V13-R28, November 2023) and NeoMedQ Glucose gel 40% monograph Queensland Health guideline PDF, 2023.Source
- [10]Kaiser JR, Bai S, Gibson N, et al. Association Between Transient Newborn Hypoglycemia and Fourth-Grade Achievement Test Proficiency: A Population-Based Study JAMA Pediatr, 2015.PMID 26301959